The addiction of cancer cells to causal gene fusions often results in amplification, in vivo, which can be exploited to reveal unidentified recurrent gene rearrangements. Based on this observation, we ...
A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...
Wells Fargo (NYSE:WFC) initiated coverage on Merus N.V. (NASDAQ:MRUS), currently trading at $41.54 with a market capitalization of $2.84 billion, with an Overweight rating and a price target of $91.00 ...
Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company announced today that the New England Journal of Medicine (NEJM) published results of the 204-patient, global, ...
In the second study, Nallasivan Palanisamy and co-workers report that 1–2% of prostate cancers harbor gene fusions involving RAF kinase genes, rather than classical ETS family transcription factors.
This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...
4d
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...
News Medical on MSN3d
RUFY1-RET fusion identified as mechanism of resistance to lorlatinib in lung cancerA new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...
Association between skeletal muscle morphometrics and overall survival among older adults with gastrointestinal cancers. Gene rearrangements/fusions identified per year.
Genetic medicines could treat certain diseases, however, the current delivery systems available—viral vectors and lipid nanoparticles (LNPs)—pose unique challenges for gene therapy applications. For ...
Here we present a case of a patient with stage IV CD-74-ROS1 fusion NSCLC discovered initially with RNA next generation sequencing (NGS) who acquired ...
A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback